Figure 1
Overexpression of LSD1 in high grade and metastasized lung adenocarcinoma. (A) The bar graph with 5–95 percentiles showing LSD1 mRNA expression in different types of lung tumors as determined by previously published transcriptome sequencing data for AC = lung adenocarcinoma (n = 40)19,20, SQ = squamous lung carcinoma (n = 9)19, CA = carcinoid (n = 69)21, SCLC = small cell lung cancer (n = 80)3. LSD1 expression is represented by Fragments Per Kilobase of exon per Million fragments mapped (FPKM). Original data are provided in Supplementary Table S1. Mann-Whitney U test was used to calculate the statistical significance. ***P < 0.001. (B) Representative images of immunostainings with LSD1 antibodies on TMAs including 182 NSCLC AC and 11 non-tumor lung tissues. Immunostaining showed only moderate LSD1 expression in normal lung tissues, but elevated LSD1 expression in NSCLC-AC. The LSD1 expression in NSCLC-AC was classified using a low, medium and high immunostaining score as shown exemplarily for low and high LSD1 expression. Scale bars indicate 100 µm. (C–E) LSD1 expression analysed by immunohistochemistry on 182 lung adenocarcinomas was correlated with tumor grades (C), lymph node metastasis (D) and KRAS mutation (E). Chi-Square tests were used to calculate the statistical significance for linear-by-linear association. *P < 0.05, ***P < 0.001 and n.s. = not significant. Original data for C-E can be found in Supplementary Table S2. (F) LSD1 expression in non-small cell lung cancer cell lines with various mutational background determined by immunoblot.
